Search

Displaying results 3361 - 3370 of 10000 in total
  1. Drug

    MK-0533

    go.drugbank.com/drugs/DB15242
    Investigational

    MK-0533 is under investigation in clinical trial NCT00543959 (Efficacy and Tolerability of MK0533 in Patients With Type 2 Diabetes (0533-005)).

  2. Drug

    Bfpet F-18

    go.drugbank.com/drugs/DB15424
    Investigational

    Bfpet F-18 is under investigation in clinical trial NCT03265431 (Evaluation of PET/MR in Patients Selected for Ablation Therapy).

  3. Drug

    MK-0752

    go.drugbank.com/drugs/DB12852
    Investigational

    Mk 0752 is under investigation in clinical trial NCT00572182 (MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer).

  4. Drug

    Adrulipase alfa

    go.drugbank.com/drugs/DB15004
    Investigational

    MS-1819 is under investigation in clinical trial NCT03481803 (A Phase IIa Study With Escalating Dose of MS1819-SD).

  5. Drug

    Abrilumab

    go.drugbank.com/drugs/DB15076
    Investigational

    Abrilumab is under investigation in clinical trial NCT01290042 (Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.).

  6. Drug

    AG-24322

    go.drugbank.com/drugs/DB13035
    Investigational

    AG-024322 has been used in trials studying the treatment of Neoplasms and Lymphoma, Non-Hodgkin.

  7. Indication

    Herpes Simplex

    go.drugbank.com/conditions/DBCOND0027882
    Drugs: Lysozyme
    Synonyms: Herpes simplex complex
  8. Drug

    Xanthinol

    go.drugbank.com/drugs/DB09092
    ApprovedWithdrawn

    [L1080] It was approved as a drug in 1998 in Canada and nowadays its status is cancelled post marketing. … [L1079] Xaninthol is known to be a potent vasodilator that can easily pass through the cell membrane and once inside the cell it causes an increase in glucose metabolism resulting in an increased energy

  9. Drug

    Maralixibat

    go.drugbank.com/drugs/DB16226
    ApprovedInvestigational

    with Alagille syndrome:[L43547] it was granted marketing authorization in Europe on 13 December 2022. … [L38834] In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended maralixibat be granted marketing authorization for the treatment of cholestatic pruritus in patients

  10. Drug

    Vandetanib

    go.drugbank.com/drugs/DB05294
    ApprovedInvestigational

    On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. … Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types.

    Synonyms: N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine, N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine